Combining cell and gene therapy in an effort to eradicate HIV

AIDS Patient Care and STDs

Volumn 30, Issue 12, 2016, Pages 534-538

  Wagner, Thor A ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

CCR5; Cell therapy; Chimeric antigen receptor; Gene therapy; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHIMERIC ANTIGEN RECEPTOR;

ARTICLE; CELL THERAPY; DISEASE ERADICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LONG TERM CARE; LYMPHOCYTE; NEOPLASM; REMISSION; T LYMPHOCYTE; VIRAL GENE THERAPY; ANIMAL; BIOLOGICAL THERAPY; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HIV-1; HUMANS;

EID: 85002640390     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0226     Document Type: Article

References (85)

1. Global Report: UNAIDS Report on the Global AIDS Epidemic 2012. Joint United Nations Programme on HIV/AIDS (UN-AIDS). Geneva: UNAIDS, 2012. ISBN 987-92-9173-996-7.
2. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: Insights from the Global Burden of Disease Study 2010. AIDS 2013;27:2003-2017.
3. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34.
4. Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012;55:1228-1235.
5. Triant VA, Josephson F, Rochester CG, et al. Adverse outcome analyses of observational data: Assessing cardiovascular risk in HIV disease. Clin Infect Dis 2012;54:408-413.
6. Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 2012;25:4-9.
7. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010; 53:124-130.
8. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727-728.
9. Crooks AM, Bateson R, Cope AB, et al. Precise quantita-tion of the latent HIV-1 reservoir: Implications for eradication strategies. J Infect Dis 2015;212:1361-1365.
10. Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014;345:179-183.
11. Wagner TA, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014;345:570-573.
12. Cohn LB, Silva IT, Oliveira TY, et al. HIV-1 integration landscape during latent and active infection. Cell 2015;160: 420-432.
13. Simonetti FR, Sobolewski MD, Fyne E, et al. Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc Natl Acad Sci U S A 2016;113:1883-1888.
14. Cartellieri M, Bachmann M, Feldmann A, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010;2010:956304.
15. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21:215-223.
16. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges. Cancer Immunol Immun-other 2012;61:953-962.
17. Maher J. Immunotherapy of malignant disease using chi-meric antigen receptor engrafted T cells. ISRN Oncol 2012;2012:278093.
18. Gilham DE, Debets R, Pule M, Hawkins RE, Abken H. CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe. Trends Mol Med 2012;18:377-384.
19. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol 2012;24:633-639.
20. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-1517.
21. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-4102.
22. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chi-meric antigen receptor-modified T cells in chronic lym-phoid leukemia. N Engl J Med 2011;365:725-733.
23. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-1518.
24. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra138.
25. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus. J Virol 2005;79:9625-9634.
26. Persaud D, Siberry GK, Ahonkhai A, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004;78:968-979.
27. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 2007;23:381-390.
28. Fischer M, Joos B, Niederost B, et al. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retro-virology 2008;5:107.
29. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
30. KaiserP,JoosB,NiederostB, WeberR,Gunthard HF, Fischer M. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/ CD8 double-negative T lymphocytes. J Virol 2007;81:9693-9706.
31. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 2009;4:e8490.
32. Yukl S, Pillai S, Li P, et al. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired trans-activation activity. Virology 2009;387:98-108.
33. Schmid A, Gianella S, von Wyl V, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PloS One 2010;5:e13310.
34. Dybul M, Chun TW, Ward DJ, et al. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor-Sparing highly active antiretroviral therapy. J Infect Dis 2000;181:1273-1279.
35. Schupbach J, Tomasik Z, Knuchel M, et al. Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with unde-tectable HIV-1 RNA under long-term HAART. J Med Virol 2006;78:1003-1010.
36. Nies-Kraske E, Schacker TW, Condoluci D, et al. Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis 2009;199:1648-1656.
37. Santosuosso M, Righi E, Lindstrom V, Leblanc PR, Poznansky MC. HIV-1 envelope protein gp120 is present at high concen trations in secondary lymphoid organs of individuals with chronic HIV-1 infection. J Infect Dis 2009;200:1050-1053.
38. Garcia MN, dos Ramos Farias MS, Avila MM, Rabinovich RD. Presence of p24-antigen associated to erythrocyte in HIV-positive individuals even in patients with undetectable plasma viral load. PLoS One 2011;6:e14544.
39. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006;80:6441-6457.
40. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007;3:e46.
41. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive anti-retroviral therapy. Proc Natl Acad Sci U S A 2008;105:3879-3884.
42. Hatano H, Delwart EL, Norris PJ, et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 2010;24:2535-2539.
43. De Boer RJ, Ribeiro RM, Perelson AS. Current estimates for HIV-1 production imply rapid viral clearance in lym-phoid tissues. PLoS Comput Biol 2010;6:e1000906.
44. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann Intern Med 2014;161:319-327.
45. Davey RT, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999;96:15109-15114.
46. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis 2010;202 Suppl 2:S270-S277.
47. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 2012;12:607-614.
48. Chun TW, Fauci AS. HIV reservoirs: Pathogenesis and obstacles to viral eradication and cure. AIDS 2012;26:1261-1268.
49. Durand CM, Blankson JN, Siliciano RF. Developing strategies for HIV-1 eradication. Trends Immunol 2012;33:554-562.
50. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005;366:549-555.
51. Contreras X, Schweneker M, Chen CS, et al. Sub-eroylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009;284:6782-6789.
52. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009;323:1304-1307.
53. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009;119:3473-3486.
54. Xing S, Bullen CK, Shroff NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011;85:6060-6064.
55. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-485.
56. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36:491-501.
57. Goulder PJ,PhillipsRE, ColbertRA,etal.Lateescape froman immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
58. Liu Y, McNevin JP, Holte S, McElrath MJ, Mullins JI. Dynamics of viral evolution and CTL responses in HIV-1 infection. PLoS One 2011;6:e15639.
59. Brumme ZL, John M, Carlson JM, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009;4:e6687.
60. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296: 1439-1443.
61. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996;2:338-342.
62. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
63. Minang JT, Trivett MT, Coren LV, et al. Nef-mediated MHC class I down-regulation unmasks clonal differences in virus suppression by SIV-specific CD8(+) T cells independent of IFN-gamma and CD107a responses. Virology 2009;391:130-139.
64. Mueller YM, De Rosa SC, Hutton JA, et al. Increased CD95/ Fas-induced apoptosis of HIV-specific CD8(+) T cells. Immunity 2001;15:871-882.
65. + T cells in HIV infection. J Immunol 2009;183:1120-1132.
66. + T cells evade Treg cell suppression. Nat Med 2011;17:989-995.
67. Kolte L, Gaardbo JC, Skogstrand K, Ryder LP, Ersboll AK, Nielsen SD. Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs. Clin Exp Immunol 2009;155:44-52.
68. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
69. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119: 2709-2720.
70. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra153.
71. Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 1991;64:1037-1046.
72. + T lymphocytes armed with universal T-cell receptors. Blood 1994;84:2878-2889.
73. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A 1997;94:11478-11483.
74. Bitton N, Verrier F, Debre P, Gorochov G. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J Immunol 1998;28:4177-4187.
75. Patel SD, Moskalenko M, Tian T, et al. T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. Cancer Gene Ther 2000;7:1127-1134.
76. MasieroS, Del Vecchio C, Gavioli R, et al. T-cell engineering bya chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 2005;12:299-310.
77. Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 2013;446:268-275.
78. MacLean AG, Walker E, Sahu GK, et al. A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol 2014;43:341-348.
79. Ali A, Kitchen SG, Chen IS, Ng HL, Zack JA, Yang OO. HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J Virol 2016;90:6999-7006.
80. Liu B, Zou F, Lu L, et al. CAR-T cells guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate the reactivated virus-latently-infected CD4+ T-lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined an-tiretroviral therapy. J Virol 2016;90:9712-9724.
81. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002;5:788-797.
82. Liu L, Patel B, Ghanem MH, et al. Novel CD4-based bis-pecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol 2015;89:6685-6694.
83. Zhen A, Kamata M, Rezek V, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 2015;23:1358-1367.
84. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
85. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-910.